PIM kinase inhibitors and methods of their use

US8822497B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Matthew Burger · Belmont, US
• Mika Lindvall · Emeryville, US
• Wooseok Han · San Ramon, US
• Jiong Lan · Moraga, US
• Gisele Nishiguchi · Arlington, US
• Cynthia Shafer · El Sobrante, US
• Cornelia Bellamacina · Dedham, US
• Kay Huh · San Mateo, US
• Gordana Atallah · Fremont, US
• Christopher McBride · Oakland, US
• William R. Antonios-McCrea · Moraga, US
• Tatiana Zavorotinskaya · Moraga, US
• Annette Walter · Mill Valley, US
• Pablo Garcia · Emeryville, US

Key dates

• Filing date: Mar 3, 2008
• Grant date: Sep 2, 2014
• Expiry date: Dec 3, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D239/28
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.